What Singapore could teach the world about disease control aol.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aol.co.uk Daily Mail and Mail on Sunday newspapers.
Takeda today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization
Japanese pharma company Takeda on Friday announced that its dengue vaccine candidate, TAK-003, prevented 84 per cent of hospitalised dengue cases and 61 per cent of symptomatic cases.The 4.5-year-long phase-3 clinical trial, which included over .
New Delhi, June 10 (IANS) Japanese pharma company Takeda on Friday announced that its dengue vaccine candidate, TAK-003, prevented 84 per cent of hospitalised